Orally administered medical composition

In order to provide to clinical practices a single pharmaceutical preparation having a controlled release part including mirabegron or a pharmaceutically acceptable salt thereof and a rapid release part including solifenacin or a pharmaceutically acceptable salt thereof: (1) provided is a single pha...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: TOYOTA HIROYASU, TSUTSUI YUUKI, HAKOMORI TADASHI
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In order to provide to clinical practices a single pharmaceutical preparation having a controlled release part including mirabegron or a pharmaceutically acceptable salt thereof and a rapid release part including solifenacin or a pharmaceutically acceptable salt thereof: (1) provided is a single pharmaceutical preparation wherein the elution profile of each medication is unchanged from conventional pharmaceutical preparations; and (2) provided is a single pharmaceutical preparation having a maximum medication elution rate of at least 90% for each medication and exhibiting a similar bioavailability to conventional pharmaceutical preparations. Furthermore, (3) a single pharmaceutical preparation is provided that exhibits good productivity whereby tableting problems are suppressed and exhibits good storage stability whereby coloration of the rapid release part thereof is suppressed. This orally administered medical composition contains (1) a controlled release part including mirabegron or a pharmaceutically acceptable salt thereof and (2) a rapid release part including solifenacin or a pharmaceutically acceptable salt thereof and calcium stearate.